Roivant Sciences Insider Sold Shares Worth $8,190,725, According to a Recent SEC Filing

Published on 03/25/2025 at 03:14 - Modifié on 03/25/2025 at 03:15

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Roivant Sciences Ltd.

Roivant Sciences Ltd. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 04:20 PM	Jul. 10
AI Mania Masks Trade War Risks	Jul. 10
Analyst recommendations: Centene, McDonald's, Oracle, Roku, Trex…	Jul. 10
Roivant Sciences Insider Sold Shares Worth $1,145,000, According to a Recent SEC Filing	Jun. 25	MT
Roivant Sciences Ltd. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 04:00 PM	Jun. 10
Roivant Sciences Insider Sold Shares Worth $8,454,808, According to a Recent SEC Filing	Jun. 06	MT
Roivant Sciences Ltd. Presents at Jefferies Global Healthcare Conference 2025, Jun-05-2025 04:20 PM	Jun. 05
Roivant Sciences Ltd., Q4 2025 Earnings Call, May 29, 2025	May. 29
Tranche Update on Roivant Sciences Ltd.'s Equity Buyback Plan announced on April 2, 2024.	May. 29	CI
Roivant Sciences Fiscal Q4 Net Loss Widens, Revenue Falls	May. 29	MT
Earnings Flash (ROIV) Roivant Posts Fiscal Q4 Net Loss $0.29 a Share, vs. FactSet Est of $0.31 Loss	May. 29	MT
Earnings Flash (ROIV) Roivant Sciences Reports Q4 Revenue $7.6M, vs. FactSet Est of $54.1M	May. 29	MT
Roivant Sciences Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2025	May. 29	CI
Roivant Sciences Insider Sold Shares Worth $10,129,810, According to a Recent SEC Filing	May. 09	MT
Roivant Sciences Insider Sold Shares Worth $1,022,000, According to a Recent SEC Filing	Apr. 23	MT
Immunovant Names New CEO, CFO	Apr. 21	MT
Roivant Sciences Ltd. - Special Call	Apr. 21
Immunovant Announces Next Phase Of Growth With Roivant Including Changes To Its Leadership Team And Additional Indications	Apr. 21	RE
Sumitomo Pharma Secures 233 Billion Yen Syndicated Loan to Refinance Debt	Mar. 26	MT
Roivant Sciences Insider Sold Shares Worth $8,190,725, According to a Recent SEC Filing	Mar. 25	MT
Immunovant Says Currently Not Planning to Seek Approval of Batoclimab for Myasthenia Gravis; Shares Drop Pre-Bell	Mar. 19	MT
Roivant Sciences Says Phase 3 MG Study Meets Primary Endpoint	Mar. 19	RE
Roivant Sciences Ltd. Presents at Leerink?s Global Healthcare Conference 2025, Mar-10-2025 10:40 AM	Mar. 10
Roivant Sciences Ltd. Presents at TD Cowen 45th Annual Healthcare Conference, Mar-04-2025 01:10 PM	Mar. 04
Roivant Sciences Unit, Arbutus File Lawsuits Against Moderna for Alleged Patent Infringement	Mar. 03	MT